Pioglitazone HCl

• CAT Number: A000405
• CAS Number: 112529-15-4
• Molecular Formula: C19H20N2O3S.HCl
• Molecular Weight: 392.9
• Purity: ≥95%
• Target: PPAR
• Solubility: >19.7mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride
• InChI: InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H
• InChIKey: GHUUBYQTCDQWRA-UHFFFAOYSA-N
• SMILES: CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3.Cl

Pioglitazone HCl (CAS 112529-15-4) is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
Pioglitazone inhibits LPS-induced iNOS expression and NO generation, and inhibition of iNOS is sufficient to protect dopaminergic neurons against LPS insult. Pioglitazone protects dopaminergic neurons against LPS insult at least via inhibiting iNOS expression and NO generation, which is potentially mediated via inhibition of p38 MAPK activity. Pioglitazone inhibits LPS-induced phosphorylation of p38 MAPK.
Pioglitazone administered orally (0.3-3 mg/kg/d for 7 days) dose dependently reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in male fatty rats. Pioglitazone improves glucose tolerance and augmentes the glycemic response to exogenous insulin and clearance of plasma triglyceride in rats.

Reference

1.Sakamoto, Junichi, et al. "Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone." Biochemical and biophysical research communications 278.3 (2000): 704-711.
2.Li, Xinbao, et al. "Preferential solvation of pioglitazone hydrochloride in some binary co-solvent mixtures according to the inverse Kirkwood–Buff integrals method." The Journal of Chemical Thermodynamics 110 (2017): 218-226.
3.Xing, Bin, et al. "Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt." Journal of Neuroinflammation 5.1 (2008): 1-11.
4.Sugiyama, Y., et al. "Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats." Arzneimittel-forschung 40.3 (1990): 263-267.